Abstract
Aim
To analyse the results of the use of Recombinant Bone Morphogenic Protein (BMP-7) for treatment of fracture nonunions at our institution.
Material and methods
From 2001 to 2006, 23 patients with fracture nonunion were treated with BMP-7 for bone healing. There were 14 male and 9 females. The mean age of patients was 45 years (Range 21-76 yrs). There were 11 femoral, 9 tibial and 3 humerus fractures. There were 4 open injuries. The average number of operations before BMP-7 insertion was 2.66 (Range 0-6). The mean time between the injury and BMP insertion was 54 months (Range 5-312). 9 patients had previous autologous bone graft inserted without union.
Results
All the fracture went on to unite within an average of 7 months (Range 4-16). 4 patients had BMP-7 insertion on its own. In another 3 patients it was mixed with allograft. In the rest of 16 patients BMP-7 was mixed with autologous bone graft. 2 patients needed BMP-7 insertion on 2 separate occasions. In all except 1 patient the original fixation of the fracture had to be revised. There were no complications from the use of BMP-7.
Conclusion
Use of recombinant BMP-7 lead to fracture union in all our patients. We believe that the use of BMP-7 improved the chances of fracture healing in persistent nonunions and it is safe and easy to use.
